FDA Prescription Drug Labeling Requirements

Prescription drug labeling in the United States is governed by a detailed federal framework administered by the Food and Drug Administration, establishing what information must appear on a drug's packaging, container, and accompanying documentation. These requirements determine how prescribers, pharmacists, and patients access critical safety and efficacy data for every approved prescription product. Failures in labeling compliance are among the most cited causes of FDA enforcement actions, including Warning Letters and drug recalls. The regulations are codified primarily under 21 CFR Part 201 and supplemented by agency guidance documents issued by the Center for Drug Evaluation and Research (CDER).

Definition and scope

Prescription drug labeling, as defined under 21 CFR § 201.1, encompasses all written, printed, or graphic matter accompanying a drug or appearing on its container or wrapper. The FDA distinguishes between two primary labeling types:

The scope of these requirements extends to all prescription drug products approved through the FDA drug approval process, including New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs) for generics, and Biologics License Applications (BLAs). Products approved under accelerated or emergency pathways carry labeling obligations that may evolve post-approval as additional safety data accumulates.

How it works

The Physician Labeling Rule (PLR), finalized by FDA in 2006 (71 Fed. Reg. 3922), restructured the format of prescription drug package inserts into a standardized, navigable document. The PLR applies to all new prescription drug and biological products submitted after June 30, 2006, and required phased compliance for previously approved products.

Under the PLR, the prescribing information must follow this ordered structure:

  1. Highlights of Prescribing Information — a one-half page summary of the most critical labeling sections, including boxed warnings, indications, dosage and administration, and contraindications.
  2. Full Table of Contents — a structured index of all sections in the complete prescribing information.
  3. Boxed Warning (if applicable) — required when the drug carries a risk serious enough to warrant the most prominent alert, such as risk of death or severe injury, set apart in a bold-bordered box.
  4. Indications and Usage — a concise statement of the approved use or uses.
  5. Dosage and Administration — specific dosage forms, strengths, and administration instructions.
  6. Warnings and Precautions — clinically significant adverse reactions and safety hazards.
  7. Adverse Reactions — all identified adverse reactions from clinical trial data and post-market reporting.
  8. Drug Interactions — clinically significant interactions with other drugs, foods, or substances.
  9. Use in Specific Populations — including pregnancy, lactation, pediatric use, and geriatric use.
  10. Clinical Pharmacology, Nonclinical Toxicology, and Clinical Studies — supporting data sections.

The FDA's adverse event reporting infrastructure feeds post-market safety data back into labeling revision processes. When new safety signals emerge, manufacturers may be required to submit a Prior Approval Supplement or a Changes Being Effected (CBE-0 or CBE-30) supplement to update labeling under 21 CFR § 314.70.

Common scenarios

Boxed warning additions: When post-market pharmacovigilance identifies a previously unrecognized serious risk, FDA may require a boxed warning addition. The agency issued over 70 new or revised boxed warnings between 2018 and 2022 across therapeutic categories, based on data aggregated through its MedWatch system (FDA MedWatch).

Generic drug labeling: Under 21 CFR § 314.94, generic drugs approved via the ANDA pathway must carry labeling that is the same as the reference listed drug (RLD), with limited exceptions. This sameness requirement means that when the brand's labeling changes, generics must update accordingly — a process coordinated through FDA's Office of Generic Drugs. More detail on the generic pathway is available at FDA Generic Drug Approval.

OTC switch labeling: When a prescription product transitions to over-the-counter status, its labeling undergoes a complete reformulation from the prescribing information format to the Drug Facts panel format required under 21 CFR § 201.66. The Drug Facts label uses defined type sizes, a standardized heading order, and plain language to serve consumer self-selection. The regulatory distinction between these two label types is detailed further under FDA Over-the-Counter Drug Regulations.

Decision boundaries

Several threshold questions determine which labeling rules apply to a specific product:

New vs. grandfathered labeling format: Products with applications submitted before June 30, 2006 were not immediately required to convert to PLR format; however, any major labeling revision triggers a mandatory conversion to the PLR structure (71 Fed. Reg. 3922).

Prescription vs. OTC classification: The regulatory boundary between prescription and OTC status under 21 U.S.C. § 353(b) determines which labeling regime applies. A drug requires prescription labeling if it cannot be safely used without professional supervision due to toxicity, method of administration, or collateral hazard.

Supplement type and urgency: When a manufacturer identifies a new safety issue, 21 CFR § 314.70 establishes three pathways — Prior Approval, CBE-30 (changes being effected in 30 days), and CBE-0 (immediate) — based on the severity and urgency of the safety information. Imminent hazard situations may additionally trigger FDA's authority to mandate labeling changes unilaterally under 21 U.S.C. § 355(o)(4).

The broader regulatory context for prescription drug oversight, including the agency's structure and enforcement tools, is accessible from the FDA Authority reference index.

Read Next

FDA Oversight of Compounding Pharmacies Compounding pharmacies occupy a distinct regulatory space within U.S. drug law, operating under statutory frameworks that differ... FDA Over-the-Counter Drug Regulations Over-the-counter (OTC) drug regulations govern the sale of medications available to consumers without a prescription,... FDA Drug Shortage Monitoring and Management Drug shortages in the United States represent a persistent supply chain risk with direct consequences for patient care, hospital...